Jump to Main Content
A review of pharmacological and clinical studies on the application of Shenling Baizhu San in treatment of Ulcerative colitis
- Qianqian Ma, Yong Ouyang, Fansu Meng, Malleshappa N. Noolvi, Stephen Paul Avvaru, Uttam A. More, Tejraj M. Aminabhavi, Manling Du, Hui Liu, Yong Zhuang, Mujuan Pang, Tiange Cai, Yu Cai
- Journal of ethnopharmacology 2019 v.244 pp. 112105
- Oriental traditional medicine, adverse effects, animal models, biomedical research, clinical trials, colitis, cough, diarrhea, dyspnea, feces, herbs, immune response, in vitro studies, in vivo studies, ingestion, intestinal microorganisms, irritable bowel syndrome, mitogen-activated protein kinase, nutritional intervention, patients, pharmacology, signal transduction, spleen, stomach
- The prescription of Shenling Baizhu San (SLBZS) was derived from the Song Dynasty “Taiping Huimin Heji Ju Fang”, which was a representative prescription for treating spleen asthenic diarrhea. The prescription comprised of 10 herbs for treating weak spleen and stomach. It describes symptoms like eating less, loose stools, cough, shortness of breath and tired limbs. SLBZS has been reported to be capable of eliminating discomfort when it is administered for treating irritable bowel syndrome and diarrhea. This traditional Chinese medicine (TCM) formula has been widely used for improving gastrointestinal dysfunction and modifying the immune response to inflammation.This review is aimed to provide the up-to-date information on the pharmacology and clinical research of SLBZS in the treatment of ulcerative colitis (UC), and to discuss the research findings and possible deficiencies, hoping to better guide the clinical application and scientific research of SLBZS in the treatment of UC.Relevant studies from 2004 to 2018 on SLBZS in the treatment of UC mechanism and curative effect were collected from ancient books, pharmacopoeia, reports, thesis via library and Digital databases (PubMed, CNKI, Google Scholar, Web of Science, SciFinder, Springer, Elsevier, etc).SLBZS could regulate inflammatory factors and intestinal flora, and ERK/p38 MAPK signaling pathway may be one of its targets. In addition, clinical research results show that SLBZS has a good therapeutic effect on UC, and the adverse reactions are small.Although SLBZS has achieved some success in the treatment of UC, there are still some scientific gaps. There is a lack of uniform standards for constructing UC animal models, and some methods of modeling through environmental and dietary interventions are not reproducible, and there is a lack of uniform dosing regimen standards. SLBZS doses follow the tradition and lack toxicological validation. Therefore, more specific toxicological research models are essential. The clinical application of SLBZS requires reassessment and standardization. Although all clinical research reports randomly assigned patients to different groups, most did not describe a detailed method of randomization and no description of the analysis data. In addition, extensive in vitro studies and further in-depth molecular studies are essential for the determination of mechanisms that have been performed in all in vivo experiments on animal models and patients.